Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Medicinal Chemistry

Medicinal Chemistry

Advancing drug discovery by applying the right medicinal chemistry approaches to deliver high-quality drug candidates

Syngene’s pool of experienced and multi-disciplinary scientists collaborate to efficiently assess hits, optimize compounds, and deliver high quality candidates in the hit-to-lead and lead optimization phases of drug discovery. Our scientists are experts not only in medicinal chemistry but are also well versed in computational chemistry, in vitro and in vivo biology, drug metabolism and pharmacokinetics, as well as toxicology, and are supported by advanced research instrumentation.

The team has a strong track record of having successfully delivered numerous preclinical and clinical candidates in collaboration with clients. Our experience includes therapeutic areas such as oncology, central nervous system, metabolic disorder, pain, inflammation, and autoimmune disorders among others.


Capabilities

Syngene’s medicinal chemistry teams offer the following services:


Hit-to-Lead

Drawing on vast scientific experience, our team optimizes hits and identifies the most promising active compounds to progress to the lead optimization stage. Our capabilities include:

  • High-throughput synthesis for hit expansion
  • Evaluation of hits for potency, selectivity, and drug-likeness
  • Conventional and computational chemistry driven design of novel analogs with early absorption, distribution, metabolism, and excretion properties
  • Route scouting and focused library synthesis
  • In vitro and in vivo screening of compounds for optimization

Lead optimization

Using the identified lead compound from the hit-to-lead stage, our scientists work on optimizing and evaluating the leads through various screening studies until a suitable preclinical candidate is ready. Our lead optimization capabilities include:

  • Design of hypothesis to optimize hits for desired potency and efficacy
  • Multi-parameter optimization of leads
  • Optimization studies for potency, selectivity, in vivo efficacy, pharmacokinetic/pharmacodynamic modeling (PK/PD) profile, safety and toxicity profile
  • Early scale-up of molecules to support in vivo efficacy and toxicity studies
  • Selection of preclinical candidates

Chemical Reaction Screening facility

Our Discovery Chemistry services also offer in-house dedicated chemical reaction screening facility that enables rapid go/no-go decisions. To know more about the facility, click here

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details